Cyrus Mozayeni co-founded of CODA Biotherapeutics, and Oncorus, where he served as President and CBO. Before Oncorus, Cyrus was VP and global head of business development and alliance management at bluebird bio (NASDAQ: BLUE), where his efforts led to a clinical-stage CAR T-cell program in collaboration with Celgene, and a successful IPO. Cyrus earned his Sc.B. in neuroscience from Brown University, his M.D. from the University of Virginia School of Medicine and his MBA from the Kellogg Graduate School of Management at Northwestern University. He is a licensed physician, and a Fellow of the Academy of Wilderness Medicine.
